

Novartis Taiwan

Novartis Asia Pacific

Novartis International

Novartis Taiwan has been audited by PricewaterhouseCoopers since 2009. The audit report for 2013 ended at 2013-12-31 is in accordance with the standards of the International Standards on Auditing (ISAs) issued by the International Auditing and Taxation Authority (IAA).

- Novartis Taiwan's financial statements for 2013 are audited by PricewaterhouseCoopers and the audit report is unqualified. The audit report for 2013 ended at 2013-12-31 is in accordance with the standards of the International Standards on Auditing (ISAs) issued by the International Auditing and Taxation Authority (IAA).

	Novartis Taiwan Novartis	Novartis Asia Pacific Novartis
Novartis Taiwan	204	19
Novartis Asia Pacific	1,860	77
Novartis International	1,600	76
Novartis (Total)	5,458	651
Novartis Taiwan (%)	86.02	98.70

- Novartis Taiwan's financial statements for 2013 are audited by PricewaterhouseCoopers and the audit report is unqualified.

Novartis Taiwan	Novartis (%)
Novartis Taiwan	725 (38.98)
Novartis Asia Pacific	440 (23.66)
Novartis International	297 (15.97)
Novartis (Total)	169 (9.09)
Novartis	167 (8.98)
Novartis	158 (8.49)
Novartis	140 (7.53)
Novartis	137 (7.37)
Novartis	124 (6.67)
Novartis (Total)	124 (6.67)
Novartis	119 (6.40)
Novartis	101 (5.43)

項目	割合(%)
項目	100/5.38
項目	100/5.38
項目	95/5.11

[CLEX123J1401](#)

- 項目

項目 15.54% (289/1860) 項目
 SOC項目 2.85% (53/1,860) 項目 2.80% (52/1,860)
 項目 2.69% (50/1,860) 項目 PT項目 1.40% (26) 項目
 項目 1.29% (24) 項目 1.08% (20) 項目

- 項目

項目 2 項目 280 項目 15.05%
 項目 SOC 項目 48.93% (137/280) 項目 46.43% (130/280)
 項目 45.36% (127/280) 項目 PT項目 項目 30.00% (84) 項目
 26.79% (75) 項目 24.64% (69) 項目

- 項目

項目 1902 項目 18 項目 29 項目
 項目 [CLEX123J1401](#) 項目 Table 3-29 項目

項目

項目

項目

項目

Source URL: <https://www.pro.novartis.com/jp-ja/products/clozaril/safety>